Advertisement

Annals of Hematology

, Volume 98, Issue 11, pp 2617–2619 | Cite as

Primary intraocular natural killer-cell lymphoma successfully treated using a multidisciplinary strategy

  • Tomoko Takimoto-Shimomura
  • Yuji ShimuraEmail author
  • Kenji Nagata
  • Tohru Inaba
  • Yoshiaki Chinen
  • Taku Tsukamoto
  • Tsutomu Kobayashi
  • Shigeo Horiike
  • Chie Sotozono
  • Junya Kuroda
Letter to the Editor

Dear Editor,

We here report an extremely rare case of primary intraocular natural killer (NK)-cell lymphoma that was successfully treated with a multidisciplinary strategy. A 70-year-old female was referred to our hospital with a complaint of blurred vision. Her medical history included hypertension, brain infarction, and surgically resected thyroid cancer. Severe vitreous opacity was observed in the right eye (Fig. 1a) and right visual acuity was reduced to 20/200. There was no tumor in the orbit (Fig. 1b). Aspiration of right vitreous fluid revealed infiltration of large abnormal lymphoid cells with oval or convoluted nuclei (Fig. 1c), which were positive for CD2, CD7, CD56, and HLA-DR, and negative for CD3, CD4, CD8, CD5, CD16, CD20, and CD57, with concomitant infiltration of normal T cells and a small fraction of CD20-positive B cells (Fig. 1d). Light chain restriction or polymerase chain reaction analysis for detection of rearrangement of the immunoglobulin heavy chain gene was...

Notes

Compliance with ethical standards

Conflicts of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in this report were in accordance with ethical standards of our institute and with the 1964 Helsinki declaration and its later amendments.

Informed consent

Informed consent was obtained from the patient described.

References

  1. 1.
    Maruyama K, Kunikata H, Sugita S, Mochizuki M, Ichinohasama R, Nakazawa T (2015) First case of primary intraocular natural killer t-cell lymphoma. BMC Ophthalmol 15:169CrossRefGoogle Scholar
  2. 2.
    Abedi F, Borovik AM, Waring D, Hariz S, Francis IC (2019) Primary intraocular natural killer/T-cell lymphoma unmasked with infective endophthalmitis after an intravitreal injection of bevacizumab. Clin Exp Ophthalmol:1–2Google Scholar
  3. 3.
    Tagawa Y, Namba K, Ogasawara R, Kanno H, Ishida S (2015) A case of mature natural killer-cell neoplasm manifesting multiple choroidal lesions: primary intraocular natural killer-cell lymphoma. Case Rep Ophthalmol 6:380–384CrossRefGoogle Scholar
  4. 4.
    Sagoo MS, Mehta H, Swampillai AJ, Cohen VM, Amin SZ, Plowman PN, Lightman S (2014) Primary intraocular lymphoma. Surv Ophthalmol 59:503–516CrossRefGoogle Scholar
  5. 5.
    Egashira M, Kawamata N, Sugimoto K, Kaneko T, Oshimi K (1999) P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood 93:599–606CrossRefGoogle Scholar
  6. 6.
    Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, Wasada I, Kinoshita T, Ohshima K, Matsuno Y, Terauchi T, Nawano S, Ishikura S, Kagami Y, Hotta T, Oshimi K (2009) Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 27:5594–5600CrossRefGoogle Scholar
  7. 7.
    Teckie S, Yahalom J (2014) Primary intraocular lymphoma: treatment outcomes with ocular radiation therapy alone. Leuk Lymphoma 55:795–801CrossRefGoogle Scholar
  8. 8.
    Shenkier TN, Blay J-Y, O’Neill BP, Poortmans P, Thiel E, Jahnke K, Abrey LE, Neuwelt E, Tsang R, Batchelor T, Harris N, Ferreri AJ, Ponzoni M, O’Brien P, Rubenstein J, Connors JM (2005) Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol 23:2233–2239CrossRefGoogle Scholar
  9. 9.
    Yamaguchi M, Kwong Y-L, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R (2011) Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 29:4410–4416CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Tomoko Takimoto-Shimomura
    • 1
  • Yuji Shimura
    • 1
    Email author
  • Kenji Nagata
    • 2
  • Tohru Inaba
    • 3
  • Yoshiaki Chinen
    • 1
  • Taku Tsukamoto
    • 1
  • Tsutomu Kobayashi
    • 1
  • Shigeo Horiike
    • 1
  • Chie Sotozono
    • 2
  • Junya Kuroda
    • 1
  1. 1.Division of Hematology and Oncology, Department of MedicineKyoto Prefectural University of MedicineKyotoJapan
  2. 2.Department of OphthalmologyKyoto Prefectural University of MedicineKyotoJapan
  3. 3.Division of Infection Control and Laboratory MedicineKyoto Prefectural University of MedicineKyotoJapan

Personalised recommendations